PMID- 32468355
OWN - NLM
STAT- MEDLINE
DCOM- 20210329
LR  - 20210329
IS  - 1179-1888 (Electronic)
IS  - 1175-0561 (Linking)
VI  - 21
IP  - 3
DP  - 2020 Jun
TI  - Topical Minocycline Foam 4%: A Review in Acne Vulgaris.
PG  - 449-456
LID - 10.1007/s40257-020-00523-1 [doi]
AB  - Topical minocycline foam 4% (Amzeeq) is approved in the USA for the treatment of 
      inflammatory lesions of non-nodular, moderate to severe acne vulgaris (acne) in 
      patients aged >/= 9 years. It was developed to minimize systemic minocycline 
      absorption and toxicity, and its high lipid content allows efficient drug 
      movement through sebum and into affected sites. The favorable in vitro resistance 
      profile of oral minocycline seen in Cutibacterium acnes (C. acnes) isolates was 
      maintained with topical minocycline foam 4%. In 12-week, phase III clinical 
      trials, once-daily topical minocycline foam 4% significantly improved both 
      inflammatory and noninflammatory lesions relative to foam vehicle in patients 
      aged >/= 9 years with moderate to severe acne and was reported by most patients to 
      be satisfactory or highly satisfactory to use. Extension trial data indicated 
      that topical minocycline foam 4% continued to be effective for up to 52 weeks' 
      therapy. Topical minocycline foam 4% was generally well tolerated in these 
      patients, with most adverse events (AEs) and all serious AEs considered to be 
      unrelated to treatment. Cutaneous AEs were uncommon, and findings from a dermal 
      safety study showed that topical minocycline foam 4% did not have any effects 
      related to phototoxicity, photoallergy, skin sensitization and skin irritation. 
      Topical minocycline foam 4% is thus a useful addition to available treatment 
      options for the management of inflammatory lesions of non-nodular, moderate to 
      severe acne in adult and pediatric patients aged >/= 9 years.
FAU - Paik, Julia
AU  - Paik J
AD  - Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. 
      demail@springer.com.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Am J Clin Dermatol
JT  - American journal of clinical dermatology
JID - 100895290
RN  - 0 (Anti-Bacterial Agents)
RN  - FYY3R43WGO (Minocycline)
SB  - IM
MH  - Acne Vulgaris/diagnosis/*drug therapy/microbiology
MH  - Administration, Cutaneous
MH  - Adolescent
MH  - Adult
MH  - Age Factors
MH  - Anti-Bacterial Agents/*administration & dosage/adverse effects
MH  - Child
MH  - Clinical Trials, Phase III as Topic
MH  - Dose-Response Relationship, Drug
MH  - Drug Resistance, Bacterial
MH  - Humans
MH  - Minocycline/*administration & dosage/adverse effects
MH  - Propionibacterium acnes/*drug effects/isolation & purification
MH  - Severity of Illness Index
MH  - Skin/microbiology
MH  - Treatment Outcome
MH  - Young Adult
EDAT- 2020/05/30 06:00
MHDA- 2021/03/30 06:00
CRDT- 2020/05/30 06:00
PHST- 2020/05/30 06:00 [pubmed]
PHST- 2021/03/30 06:00 [medline]
PHST- 2020/05/30 06:00 [entrez]
AID - 10.1007/s40257-020-00523-1 [pii]
AID - 10.1007/s40257-020-00523-1 [doi]
PST - ppublish
SO  - Am J Clin Dermatol. 2020 Jun;21(3):449-456. doi: 10.1007/s40257-020-00523-1.